Volume 20 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
MA Lu-yao, LIN Ping, WANG Qin, REN Qian. Screening and intervention of sarcopoenia in elderly patients with chronic heart failure[J]. Chinese Journal of General Practice, 2022, 20(3): 419-423. doi: 10.16766/j.cnki.issn.1674-4152.002367
Citation: MA Lu-yao, LIN Ping, WANG Qin, REN Qian. Screening and intervention of sarcopoenia in elderly patients with chronic heart failure[J]. Chinese Journal of General Practice, 2022, 20(3): 419-423. doi: 10.16766/j.cnki.issn.1674-4152.002367

Screening and intervention of sarcopoenia in elderly patients with chronic heart failure

doi: 10.16766/j.cnki.issn.1674-4152.002367
Funds:

 2018Z05

 2018KY593

 2019KY502

 杭卫发〔2021〕21号

  • Received Date: 2021-02-03
    Available Online: 2022-08-13
  •   Objective  To screen the incidence of sarcopoenia in elderly inpatients with chronic heart failure (CHF) and to evaluate the effect of exercise training and nutritional support in combination with standard heart-failure treatment on the improvement in sarcopoenia and cardiac function in elderly inpatients with CHF.  Methods  Two hundred elderly inpatients with CHF who were in the Hangzhou Third People's Hospital from January 2018 to February 2020 were collected to be screened for sarcopoenia. The differences of cardiac function, sarcopoenia, in the 200 selected patients were observed. The selected patients with CHF combined with sarcopoenia were randomly divided into control (standard heart-failure treatment, 33 cases) and observation (exercise training+nutritional support+standard heart-failure treatment, 33 cases) groups. After two months of treatment, the improvement in sarcopoenia and cardiac function were compared between the two groups.  Results  (1) The incidence of sarcopoenia in elderly inpatients with CHF was 33%. (2) In patients with CHF complicated with sarcopoenia and those who without sarcopoenia, NT-proBNP levels were (1 559.59±485.95) pg / mL vs. (1 362.60±336.75) pg / mL, the LVEFs were (45.56±4.25) % vs. (46.98±3.12) %, and the proportions of cardiac function Ⅲ were 37(56.06%) vs. 53(39.55%), the difference was statistically significant respectively. (3) After treatment, between two groups, the 6 min walking distance, appendicular muscle mass, grip strength, and GDF-11 level of the observation group were all higher; GDF-15 level was lower in the observation group (all P < 0.05). The LVEF and NYHA cardiac-function grading in the observation group also improved compared with that of the control group (all P < 0.05). (4) Multiple linear-regression analysis showed that the GDF-15 level was inversely correlated with appendicular muscle mass and 6 min walking distance (β=-0.449, -0.708, all P < 0.05), GDF-11 level was positively correlated with appendicular muscle mass and grip strength (β=0.537, 0.759, all P < 0.05).  Conclusion  Sarcopoenia has a high incidence in elderly inpatients with CHF. Exercise training and nutritional support combined with standard heart-failure treatment can improve sarcopoenia and cardiac function in elderly patients with CHF complicated with sarcopoenia. GDF-15 and GDF-11 can be used as clinical-observation indices in patients with sarcopoenia.

     

  • loading
  • [1]
    CRUZ-JENTOFT A J, BAHAT G, BAUER J, et al. Sarcopenia: Revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(4): 16-31.
    [2]
    LENA A, ANKER M S, SPRINGER J. Muscle wasting and sarcopenia in heart failure: The current state of science[J]. Int J Mol Sci, 2020, 21(18): 6549. doi: 10.3390/ijms21186549
    [3]
    OBA K, ISHIKAWA J, TAMURA Y, et al. Serum growth differentiation factor 15 level is associated with muscle strength and lower extremity function in older patients with cardiometabolic disease[J]. Geriatr Gerontol Int, 2020, 20(10): 980-987. doi: 10.1111/ggi.14021
    [4]
    ZHOU Y, SHARMA N, DUKES D, et al. GDF11 treatment attenuates the recovery of skeletal muscle function after injury in older rats[J]. AAPS J, 2017, 19(2): 431-437. doi: 10.1208/s12248-016-0024-x
    [5]
    DENT E, MORLEY J E, CRUZ-JENTOFT A J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management[J]. J Nutr Health Aging. 2018, 22(10): 1148-1161. doi: 10.1007/s12603-018-1139-9
    [6]
    潘春奇, 菅颖, 倪斌, 等. 沙库巴曲缬沙坦对射血分数降低的缺血性心肌病患者心肌损伤和炎症因子的影响[J]. 中华全科医学, 2020, 18(11): 1848-1850, 1945. doi: 10.16766/j.cnki.issn.1674-4152.001635

    PAN CQ, JIAN Y, NI B, et al. The effect of sacubitril/valsartan on myocardial injury and inflammatory factors in ischemic cardiomyopathy with reduced ejection fraction[J]. Chin J of Gen Prac, 2020, 18(11): 1848-1850, 1945. doi: 10.16766/j.cnki.issn.1674-4152.001635
    [7]
    CHEN L K, LIU L K, WOO J, et al. Sarcopenia in Asia: Consensus report of the Asia Working Group for Sarcopenia[J]. J Am Med Dir Assoc, 2014, 15(2): 95-101. doi: 10.1016/j.jamda.2013.11.025
    [8]
    王宙, 周琳, 刘洋, 等. 慢性心力衰竭的流行病学研究现状及其防治研究进展[J]. 中国循证心血管医学杂志, 2019, 11(8): 1022-1024. doi: 10.3969/j.issn.1674-4055.2019.08.36

    WANG Z, ZHOU L, LIU Y, et al. Current situation of epidemiology and prevention research of chronic heart failure[J]Chin J Evid Based Cardiovasc Med, 2019, 11(8): 1022-1024. doi: 10.3969/j.issn.1674-4055.2019.08.36
    [9]
    EMAMI A, SAITOH M, VALENTOVA M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)[J]. Eur J Heart Fail, 2018, 20(11): 1580-1587. doi: 10.1002/ejhf.1304
    [10]
    CURCIO F, TESTA G, LIGUORI I, et al. Sarcopenia and heart failure[J]. Nutrients, 2020, 12(1): 211. doi: 10.3390/nu12010211
    [11]
    SUZUKI T, PALUS S, SPRINGER J. Skeletal muscle wasting in chronic heart failure[J]. ESC Heart Fail, 2018, 5(6): 1099-1107.
    [12]
    LONCAR G, SPRINGER J, ANKER M, et al. Cardiac cachexia: Hic et nunc[J]. J Cachexia Sarcopenia Muscle, 2016, 7(3): 246-260.
    [13]
    BARBALHO S M, FLATO U A P, TOFANO R J, et al. Physical exercise and myokines: Relationships with sarcopenia and cardiovascular complications[J]. Int J Mol Sci, 2020, 21(10): 3607.
    [14]
    YIN J, LU X, QIAN Z, et al. New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure[J]. Theranostics, 2019, 9(14): 4019-4029.
    [15]
    NICHOLS S, MCGREGOR G O, AL-MOHAMMAD A, et al. The effect of protein and essential amino acid supplementation on muscle strength and performance in patients with chronic heart failure: A systematic review[J]. Eur J Nutr, 2020, 59(5): 1785-1801.
    [16]
    NASEEB M A, VOLPE S L. Protein and exercise in the prevention of sarcopenia and aging[J]. Nutr Res, 2017, 40: 1-20.
    [17]
    SEMBA R D, GONZALEZ-FREIRE M, TANAKA T, et al. Elevated plasma growth and differentiation factor 15 is associated with slower gait speed and lower physical performance in healthy community-dwelling adults[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(1): 175-180.
    [18]
    TANAKA R, SUGIURA H, YAMADA M, et al. Physical inactivity is associated with decreased growth differentiation factor 11 in chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1333-1342.
    [19]
    EGERMAN M A, GLASS D J. The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis[J]. Crit Rev Biochem Mol Biol, 2019, 54(2): 174-183.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Article Metrics

    Article views (339) PDF downloads(8) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return